Valneva SE (VALN) Long-Term Deferred Tax (2020 - 2026)
Valneva SE (VALN) posted Long-Term Deferred Tax of $9.1 million for Q1 2026, down 6.27% sequentially from $9.7 million in Q4 2025, and up 8.78% YoY from $8.4 million in Q1 2025.
Analysis
Valneva SE (VALN) Long-Term Deferred Tax (2020 - 2026) Analysis & Trends
Valneva SE has reported Long-Term Deferred Tax for 7 years, with the latest figure at $9.1 million in Q1 2026.
- Quarterly Long-Term Deferred Tax rose 8.78% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (up 8.78% YoY) and the FY2025 annual result came in at $9.7 million, down 6.77% from the prior year.
- Long-Term Deferred Tax eased to $9.1 million in Q1 2026 per VALN's latest filing, from $9.7 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $223.6 million in Q4 2023 and troughed at $2.9 million in Q2 2022.
- A 5-year average of $20.6 million and a median of $8.6 million in 2025 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax jumped 3788.67% in 2023, then tumbled 95.41% in 2024.
- Over 5 years, Long-Term Deferred Tax stood at $5.8 million in 2022, then jumped by 3788.67% to $223.6 million in 2023, then tumbled by 95.41% to $10.3 million in 2024, then dropped by 5.57% to $9.7 million in 2025, then retreated by 6.27% to $9.1 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $9.1 million, $9.7 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Valneva SE | 580.64 Mn | 439.38 Mn | 1.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.83 Mn |
| Mar 31, 2026 | 9.08 Mn |
| Dec 31, 2025 | 9.69 Mn |
| Sep 30, 2025 | 8.58 Mn |
| Jun 30, 2025 | 9.07 Mn |
| Mar 31, 2025 | 8.35 Mn |
| Dec 31, 2024 | 10.26 Mn |
| Sep 30, 2024 | 12.81 Mn |
| Jun 30, 2024 | 8.25 Mn |
| Mar 31, 2024 | 7.61 Mn |
| Dec 31, 2023 | 7.09 Mn |
| Sep 30, 2023 | 10.00 Mn |
| Jun 30, 2023 | 10.82 Mn |
| Mar 31, 2023 | 6.60 Mn |
| Dec 31, 2022 | 5.75 Mn |
| Sep 30, 2022 | 2.97 Mn |
| Jun 30, 2022 | 2.86 Mn |
| Mar 31, 2022 | 3.71 Mn |
| Dec 31, 2021 | 4.10 Mn |
| Dec 31, 2020 | 6.64 Mn |